메뉴 건너뛰기




Volumn 17, Issue 5, 2011, Pages 1181-1189

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: Relationship to tumor volume, clinical stage and changes in tumor burden

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GEMCITABINE; MESOTHELIN; PEMETREXED; PLATINUM;

EID: 79952263632     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1929     Document Type: Article
Times cited : (96)

References (32)
  • 2
    • 23044436187 scopus 로고    scopus 로고
    • Malignant mesothelioma
    • DOI 10.1016/S0140-6736(05)67025-0, PII S0140673605670250
    • Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
    • (2005) Lancet , vol.366 , Issue.9483 , pp. 397-408
    • Robinson, B.W.S.1    Musk, A.W.2    Lake, R.A.3
  • 4
    • 0032952875 scopus 로고    scopus 로고
    • Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
    • discussion 63-5
    • Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
    • (1999) J Thorac Cardiovasc Surg , vol.117 , pp. 54-63
    • Sugarbaker, D.J.1    Flores, R.M.2    Jaklitsch, M.T.3    Richards, W.G.4    Strauss, G.M.5    Corson, J.M.6
  • 5
    • 4644362833 scopus 로고    scopus 로고
    • Pleural mesothelioma: Little evidence, still time to do trials
    • DOI 10.1016/S0140-6736(04)17108-0, PII S0140673604171080
    • Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-5. (Pubitemid 39296609)
    • (2004) Lancet , vol.364 , Issue.9440 , pp. 1183-1185
    • Treasure, P.T.1    Sedrakyan, A.2
  • 6
    • 68349110548 scopus 로고    scopus 로고
    • Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia
    • Hasani A, Alvarez JM, Wyatt JM, Bydder S, Millward M, Byrne M, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4: 1010-6.
    • (2009) J Thorac Oncol , vol.4 , pp. 1010-1016
    • Hasani, A.1    Alvarez, J.M.2    Wyatt, J.M.3    Bydder, S.4    Millward, M.5    Byrne, M.6
  • 7
    • 0347087214 scopus 로고    scopus 로고
    • Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma
    • DOI 10.1016/S0169-5002(03)00292-7
    • van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004;43:63-9. (Pubitemid 38096293)
    • (2004) Lung Cancer , vol.43 , Issue.1 , pp. 63-69
    • Van Klaveren, R.J.1    Aerts, J.G.J.V.2    De Bruin, H.3    Giaccone, G.4    Manegold, C.5    Van Meerbeeck, J.P.6
  • 8
    • 0346456852 scopus 로고    scopus 로고
    • Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: Report of four cases
    • DOI 10.1016/j.lungcan.2003.07.005
    • Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 2004;43:71-4. (Pubitemid 38096294)
    • (2004) Lung Cancer , vol.43 , Issue.1 , pp. 71-74
    • Monetti, F.1    Casanova, S.2    Grasso, A.3    Cafferata, M.A.4    Ardizzoni, A.5    Neumaier, C.E.6
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6
  • 10
    • 1342267614 scopus 로고    scopus 로고
    • Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
    • DOI 10.1093/annonc/mdh059
    • Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15: 257-60. (Pubitemid 38262625)
    • (2004) Annals of Oncology , vol.15 , Issue.2 , pp. 257-260
    • Byrne, M.J.1    Nowak, A.K.2
  • 12
    • 33645974029 scopus 로고    scopus 로고
    • Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
    • Oxnard GR, Armato SG III, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 2006;52:141-8.
    • (2006) Lung Cancer , vol.52 , pp. 141-148
    • Oxnard, G.R.1    Armato III, S.G.2    Kindler, H.L.3
  • 15
    • 77951017506 scopus 로고    scopus 로고
    • A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters
    • Nowak AK, Francis RJ, Phillips MJ, Millward MJ, Van Der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
    • (2010) Clin Cancer Res , vol.16 , pp. 2409-2417
    • Nowak, A.K.1    Francis, R.J.2    Phillips, M.J.3    Millward, M.J.4    Van Der Schaaf, A.A.5    Boucek, J.6
  • 16
    • 2942722294 scopus 로고    scopus 로고
    • Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis
    • DOI 10.1378/chest.125.6.2356
    • Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004;125: 2356-60. (Pubitemid 38788210)
    • (2004) Chest , vol.125 , Issue.6 , pp. 2356-2360
    • Kwek, B.H.1    Aquino, S.L.2    Fischman, A.J.3
  • 17
    • 0029685127 scopus 로고    scopus 로고
    • Management of recurrent colorectal cancer: Another look at carcinoembryonic antigen-detected recurrence
    • Vauthey JN, Dudrick PS, Lind DS, Copeland EM III. Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence. Dig Dis 1996;14:5-13. (Pubitemid 126478229)
    • (1996) Digestive Diseases , vol.14 , Issue.1 , pp. 5-13
    • Vauthey, J.N.1    Dudrick, P.S.2    Lind, D.S.3    Copeland III, E.M.4
  • 18
    • 3042598857 scopus 로고    scopus 로고
    • Clinical utility of cytokeratins as tumor markers
    • DOI 10.1016/j.clinbiochem.2004.05.009, PII S0009912004001316
    • Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40. (Pubitemid 38845016)
    • (2004) Clinical Biochemistry , vol.37 , Issue.7 , pp. 529-540
    • Barak, V.1    Goike, H.2    Panaretakis, K.W.3    Einarsson, R.4
  • 20
    • 0025939625 scopus 로고
    • Clinical applications of serum tumor markers
    • Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-38.
    • (1991) Ann Intern Med , vol.115 , pp. 623-638
    • Bates, S.E.1
  • 21
    • 13844289439 scopus 로고    scopus 로고
    • Screening for colorectal cancer - Now and the near future
    • DOI 10.1053/j.seminoncol.2004.09.031
    • Bromer MQ, Weinberg DS. Screening for colorectal cancer-now and the near future. Semin Oncol 2005;32:3-10. (Pubitemid 40250121)
    • (2005) Seminars in Oncology , vol.32 , Issue.1 SPEC. ISS , pp. 3-10
    • Bromer, M.Q.1    Weinberg, D.S.2
  • 22
    • 34247881741 scopus 로고    scopus 로고
    • Prostate cancer: Epidemiology, screening, and biomarkers
    • Chodak G. Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006;8Suppl 2:S3-8.
    • (2006) Rev Urol , vol.8 , Issue.SUPPL. 2
    • Chodak, G.1
  • 23
    • 0030069718 scopus 로고    scopus 로고
    • Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers
    • DOI 10.1073/pnas.93.1.136
    • Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40. (Pubitemid 26041483)
    • (1996) Proceedings of the National Academy of Sciences of the United States of America , vol.93 , Issue.1 , pp. 136-140
    • Chang, K.1    Pastan, I.2
  • 25
    • 37249061157 scopus 로고    scopus 로고
    • Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions
    • discussion 72
    • Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 72.
    • (2008) Ann Thorac Surg , vol.85 , pp. 265-272
    • Pass, H.I.1    Wali, A.2    Tang, N.3    Ivanova, A.4    Ivanov, S.5    Harbut, M.6
  • 26
    • 77954738635 scopus 로고    scopus 로고
    • Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma
    • Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-22.
    • (2010) J Clin Oncol , vol.28 , pp. 3316-3322
    • Wheatley-Price, P.1    Yang, B.2    Patsios, D.3    Patel, D.4    Ma, C.5    Xu, W.6
  • 29
    • 51849148011 scopus 로고    scopus 로고
    • Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study
    • Boucek JA, Francis RJ, Jones CG, Khan N, Turlach BA, Green AJ. Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study. Phys Med Biol 2008;53:4213-30.
    • (2008) Phys Med Biol , vol.53 , pp. 4213-4230
    • Boucek, J.A.1    Francis, R.J.2    Jones, C.G.3    Khan, N.4    Turlach, B.A.5    Green, A.J.6
  • 30
    • 55349134617 scopus 로고    scopus 로고
    • National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
    • Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
    • (2008) Clin Chem , vol.54
    • Sturgeon, C.M.1    Duffy, M.J.2    Stenman, U.H.3    Lilja, H.4    Brunner, N.5    Chan, D.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.